Výsledky vyhledávání

Akademický článek

Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment

Autor: Shuai Ye, Dinara Sharipova, Marya Kozinova, Lilli Klug, Jimson D’Souza, Martin G. Belinsky, Katherine J. Johnson, Margret B. Einarson, Karthik Devarajan, Yan Zhou, Samuel Litwin, Michael C. Heinrich, Ronald DeMatteo, Margaret von Mehren, James S. Duncan, Lori Rink

Publikováno v: JCI Insight, Vol 6, Iss 2 (2021)

Management of gastrointestinal stromal tumors (GISTs) has been revolutionized by the identification of activating mutations in KIT and PDGFRA and clinical application of RTK inhibitors in advanced disease. Stratification of GISTs into molecularly def

Externí odkaz: https://doaj.org/article/bc77aa077101497c8a5b94060a37a94d

Zobrazit plný text záznamu

Akademický článek

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST

Autor: Martin G. Belinsky, Kathy Q. Cai, Yan Zhou, Biao Luo, Jianming Pei, Lori Rink, Margaret von Mehren

Publikováno v: BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)

Abstract Background Most gastrointestinal stromal tumors (GISTs) harbor mutually exclusive gain of function mutations in the receptor tyrosine kinase (RTK) KIT (70–80%) or in the related receptor PDGFRA (~10%). These GISTs generally respond well to

Externí odkaz: https://doaj.org/article/9eee5c1bb5b142d7958c1fdf045c394f

Zobrazit plný text záznamu

Akademický článek

ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.

Autor: Lori Rink, Michael F Ochs, Yan Zhou, Margaret von Mehren, Andrew K Godwin

Publikováno v: PLoS ONE, Vol 8, Iss 1, p e54477 (2013)

Although imatinib mesylate (IM) has transformed the treatment of gastrointestinal stromal tumors (GIST), many patients experience primary/secondary drug resistance. In a previous study, we identified a gene signature, consisting mainly of Kruppel-ass

Externí odkaz: https://doaj.org/article/86b6506b8f7e4ab0a098bf2bf1064793

Zobrazit plný text záznamu

Data from Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor

Autor: Lori Rink, Margaret von Mehren, Andrew K. Godwin, Yan Zhou, Karthik Devarajan, Lawrence Gersz, Martin G. Belinsky, Harsh B. Pathak, Phillip Zook

Purpose: Gastrointestinal stromal tumors (GIST) generally harbor activating mutations in the receptor tyrosine kinase KIT or in the related platelet-derived growth factor receptor alpha (PDGFRA). GIST treated with imatinib mesylate or second-line the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b45a66f944fac0ac581e2f16a5b0d7a
https://doi.org/10.1158/1078-0432.c.6526160

Zobrazit plný text záznamu

Data from Detection of Treatment-Induced Changes in Signaling Pathways in Gastrointestinal Stromal Tumors Using Transcriptomic Data

Autor: Andrew K. Godwin, Burton Eisenberg, Takahiro Taguchi, Sarah Mburu, Chi Tarn, Lori Rink, Michael F. Ochs

Cell signaling plays a central role in the etiology of cancer. Numerous therapeutics in use or under development target signaling proteins; however, off-target effects often limit assignment of positive clinical response to the intended target. As di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9acf07925869bdcb2b5126c6f1ad351b
https://doi.org/10.1158/0008-5472.c.6500261

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání